Greenleaf Trust Has $654,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

Greenleaf Trust increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,894 shares of the life sciences company’s stock after purchasing an additional 235 shares during the quarter. Greenleaf Trust’s holdings in Illumina were worth $654,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in shares of Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares during the last quarter. Primecap Management Co. CA lifted its position in Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after acquiring an additional 87,599 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after purchasing an additional 54,319 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after purchasing an additional 631,294 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 5.3 %

Shares of ILMN opened at $124.20 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market cap of $19.70 billion, a price-to-earnings ratio of -12.47 and a beta of 1.10. The stock has a fifty day moving average price of $138.57 and a two-hundred day moving average price of $135.43. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the company posted $0.33 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Barclays lowered their target price on Illumina from $145.00 to $130.00 and set an “equal weight” rating on the stock in a report on Monday. Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada increased their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners boosted their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.